Scribe Therapeutics Inc. announced a strategic collaboration with Sanofi for the use of Scribe's CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer. The agreement grants Sanofi non-exclusive rights to Scribe's proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies. Scribe's suite of custom engineering genome editing and delivery tools called CasX- Editors (XE), based on novel foundations such as the CasX enzyme, will support Sanofi's expanding pipeline of NK cell therapeutics for oncology.